LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Accueil・Liste d'Actions・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Ouvert

Secteur Soins de santé

1.85 -1.07

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.76

Max

1.99

Chiffres clés
By Trading Economics
Ventes	2M
BPA	-0.34
Employés	405

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+46.28 upside

Dividendes
By Dow Jones
Prochains Résultats	6 nov. 2024

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-2.3M 114M
Ouverture précédente	2.92
Clôture précédente	1.85

Sentiment de l'Actualité

By Acuity

34%

66%

93 / 390 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

1.54 / 2 Support & Résistance

Sangamo Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 nov. 2024, 23:05 UTC

Actualités

Fitch Affirms Australia's Sovereign AAA Rating, But Warns Of Mounting Budget Risks

3 nov. 2024, 21:12 UTC

Résultats

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects -- Update

3 nov. 2024, 20:59 UTC

Résultats

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects

3 nov. 2024, 23:34 UTC

Actualités

Stocks Poised for Lower Open -- Barrons.com

3 nov. 2024, 23:16 UTC

Actualités

Résultats

Berkshire Hathway Earnings Weren't as Bad as They Looked -- Barrons.com

3 nov. 2024, 22:50 UTC

Acquisitions, Fusions, Rachats

Santos Says Working Interest in PNG LNG Now 39.9%

3 nov. 2024, 22:50 UTC

Acquisitions, Fusions, Rachats

Santos Says Kumul to Assume $90 Million of Project Finance Debt Associated With Stake

3 nov. 2024, 22:49 UTC

Acquisitions, Fusions, Rachats

Santos Says Final Payment Takes Total Cash Consideration to $602 Million

3 nov. 2024, 22:49 UTC

Acquisitions, Fusions, Rachats

Santos Receives Final $241 Million Payment From Kumul

3 nov. 2024, 22:48 UTC

Acquisitions, Fusions, Rachats

Santos Completes Sale of 2.6% Interest in PNG LNG to Kumul Petroleum

3 nov. 2024, 20:37 UTC

Résultats

Westpac FY 2024 Deposits Increased 5% to A$674 Billion

3 nov. 2024, 20:37 UTC

Résultats

Westpac FY 2024 Loans Increased 4% to A$807 Billion

3 nov. 2024, 20:37 UTC

Résultats

Westpac FY 2024 Impairment Charges 7 Bps of Loans

3 nov. 2024, 20:37 UTC

Résultats

Westpac FY 2024 Operating Expenses A$10.94 Billion, Up 7% Excluding Notable Items

3 nov. 2024, 20:36 UTC

Résultats

Westpac FY 2024 Non-Interest Income A$2.84 Billion, Down 15%

3 nov. 2024, 20:35 UTC

Résultats

Westpac FY 2024 CET1 Level 2 Capital Ratio 12.5%, Up 11 Bps

3 nov. 2024, 20:35 UTC

Résultats

Westpac Raises Share Buyback Program by A$1 Billion

3 nov. 2024, 20:35 UTC

Résultats

Westpac Final Dividend A$0.76/Share

3 nov. 2024, 20:33 UTC

Résultats

Westpac FY 2024 Net Interest Margin Down 1 Bps at 1.95%

3 nov. 2024, 20:32 UTC

Résultats

Westpac FY 2024 Revenue A$21.59 Billion, Flat on FY 2023

3 nov. 2024, 20:32 UTC

Résultats

Westpac FY Net Profit A$6.99 Billion, Down 3%

3 nov. 2024, 18:09 UTC

Actualités

Boeing Had a Big Week. This One Is Even Bigger. -- Barrons.com

3 nov. 2024, 10:30 UTC

Actualités

Fed Prepares Rate Cut Amid Economic Contradictions -- WSJ

3 nov. 2024, 03:00 UTC

Actualités

Disgraced Lebanese Central Banker Who Was a Fugitive Now Awaits His Fate -- WSJ

2 nov. 2024, 13:53 UTC

Actualités

Résultats

Acquisitions, Fusions, Rachats

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2 nov. 2024, 13:44 UTC

Résultats

Acquisitions, Fusions, Rachats

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov. 2024, 13:00 UTC

Actualités

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2 nov. 2024, 12:58 UTC

Résultats

Acquisitions, Fusions, Rachats

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov. 2024, 12:48 UTC

Actualités

Résultats

Acquisitions, Fusions, Rachats

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2 nov. 2024, 12:32 UTC

Résultats

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

Comparaison

Variation de prix

Sangamo Therapeutics Inc prévision

Objectif de Prix

By TipRanks

46.28% hausse

Prévisions sur 12 Mois

Moyen 2.75 USD 46.28%

Haut 5 USD

Bas 1 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

6 ratings

Achat

Maintien

Vente

Basé sur 6 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

1.54 / 2Support & Résistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

93 / 390Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

EBITDA

Bénéfice d'exploitation

À Propos Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company is focused on translating science into medicines that transform the lives of patients with serious diseases. Its product candidates include Giroctocogene fitelparvovec (SB-525), ST-920, SAR445136, ST-400 and TX200. Its SB-525, is a lead product candidate, a gene therapy for the treatment of hemophilia A. Its ST-920, is a gene therapy product candidate for the treatment of fabry disease. SAR445136, is its cell therapy product candidate for the treatment of sickle cell disease (SCD). Its ST-400 is a cell therapy product candidate for the treatment of transfusion dependent beta thalassemia. Its TX200, is a chimeric antigen receptor (CAR), engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection.